Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Comprehensive clinical development programs being initiated for each investigational candidate
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Subscribe To Our Newsletter & Stay Updated